Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
Do you have a question or comment? Please get in touch. We’d love to hear from you via one of the methods below.
Address
2929 Arch Street, Suite 600 Philadelphia, PA, 19104, US
Phone
+1 267 759 3100
Email / Link
General Inquiries: contactus@cabalettabio.com
Investors: investors@cabalettabio.com
Whistleblower Reporting: https://irdirect.net/CABA/whistleblower_iframe